CD33 and leukemia: By targeting both tumor-associated antigens, i.e. CD19 and CD33, at the same time, selectivity of elimination may be achieved and immune escape will likely be reduced, because antigen double-negative leukemia cell clones are less likely to be selected than single-negative ones [8, 9].